← Back to Screener
Actuate Therapeutics, Inc. Common stock (ACTU)
Price$2.62
Favorite Metrics
Price vs S&P 500 (26W)-79.09%
Price vs S&P 500 (4W)-11.20%
Market Capitalization$54.77M
All Metrics
Book Value / Share (Quarterly)$0.34
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.83
Price vs S&P 500 (YTD)-66.39%
EPS (TTM)$-1.07
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-1.07
EPS (Annual)$-1.06
ROI (Annual)-266.87%
Cash / Share (Quarterly)$0.57
ROA (Last FY)-158.36%
EBITD / Share (TTM)$-1.07
Cash Flow / Share (Annual)$-0.83
P/B Ratio6.91x
P/B Ratio (Quarterly)17.95x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-10.42x
ROA (TTM)-205.80%
EPS Incl Extra (Annual)$-1.06
Current Ratio (Annual)2.39x
Quick Ratio (Quarterly)2.31x
3-Month Avg Trading Volume0.09M
52-Week Price Return-71.93%
Revenue / Employee (TTM)$0
52-Week High$11.99
EPS Excl Extra (Annual)$-1.06
26-Week Price Return-70.35%
Quick Ratio (Annual)2.31x
13-Week Price Return-56.08%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)2.39x
Enterprise Value$42.016
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.57
3-Month Return Std Dev104.13%
Net Income / Employee (TTM)$-2
ROE (Last FY)-280.51%
EPS Basic Excl Extra (Annual)$-1.06
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-1.07
ROI (TTM)-101.28%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-107.03%
Year-to-Date Return-62.25%
5-Day Price Return26.92%
EPS Normalized (Annual)$-1.06
Month-to-Date Return-15.69%
EBITD / Share (Annual)$-1.07
LT Debt / Equity (Annual)0.05x
LT Debt / Equity (Quarterly)0.05x
EPS Basic Excl Extra (TTM)$-1.07
P/B Ratio (Annual)17.95x
Book Value / Share (Annual)$0.34
Price vs S&P 500 (13W)-58.95%
Beta1.87x
Revenue / Share (TTM)$0.00
ROE (TTM)-105.63%
52-Week Low$1.58
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ACTUActuate Therapeutics, Inc. Common stock | — | — | — | — | $2.62 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies targeting GSK-3, a key regulator of tumor cell survival and growth. The company's lead candidate, elraglusib, is designed to inhibit GSK-3B and disrupt oncogenic signaling pathways in difficult-to-treat cancers. Actuate is pursuing a novel mechanism of action to address cancers with limited therapeutic options.